Jacob Thomas
Medical Oncology · Los Angeles, CANPI 1811262967
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,295 of the $4,701 with a category attached, or 70.1%. 25 manufacturers reported payments, led by Coherus Oncology, Inc. at 46.3% of the total. Reporting peaked in 2024 at $2,319 and has fallen 97.0% since, to $69 in 2025. That places this record below the midpoint for medical oncology clinicians in CA, where the typical reported total is $4,042.
Across 56 payments — averaging $83.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coherus Oncology, Inc.$2K
- Pfizer$1K
- Merck$161
- Sobi, Inc$126
- Novartis$104
- Array Biopharma Inc$81
- plus $604 from 19 others
Across 191 payments — averaging $6363.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$369K
- Exelixis Inc.$309K
- Aadi Bioscience, Inc.$248K
- Beone Medicines USA, Inc.$110K
- E.r. Squibb & Sons, L.L.C.$97K
- Regeneron$47K
- plus $34K from 3 others
What the payments were for
- Speaking & faculty fees$3,29570%
- Travel & lodging$1363%
- Food & beverage$1,27027%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coherus Oncology, Inc. | 2 | $2,177 |
| Pfizer | 6 | $1,448 |
| Merck | 9 | $161 |
| Sobi, Inc | 5 | $126 |
| Novartis | 4 | $104 |
| Array Biopharma Inc | 1 | $81 |
| Taiho Oncology, Inc. | 3 | $66 |
| Beone Medicines USA, Inc. | 2 | $48 |
| Eisai Inc. | 2 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Incyte Corporation | 2 | $41 |
| AstraZeneca(2 entities) | 2 | $37 |
| Bayer | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Amgen | 2 | $34 |
| Regeneron Healthcare Solutions, Inc. | 1 | $32 |
| Johnson & Johnson | 1 | $26 |
| Bristol Myers Squibb | 1 | $24 |
| Exelixis Inc. | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Ipsen Biopharmaceuticals, Inc | 1 | $23 |
| AVEO Pharmaceuticals, Inc. | 1 | $23 |
| AbbVie | 1 | $17 |
| Sirtex Medical Inc | 1 | $13 |
| Dova Pharmaceuticals | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,701 in reported general payments places this provider in the 50th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 23 | $514,651 |
| LumakrasSotorasib | 14 | $298,011 |
| RetevmoSelpercatinib | 17 | $270,716 |
| MekinistTrametinib Dimethyl Sulfoxide | 11 | $185,861 |
| TafinlarDabrafenib Mesylate | 11 | $157,154 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 18 | $424 |
| Gabapentin | 22 | $287 |
| Levothyroxine Sodium | 34 | $276 |
| Ondansetron Hcl | 19 | $210 |
| Pantoprazole Sodium | 13 | $85 |
| Prednisone | 17 | $65 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Eisai Inc.Lenvima | $45 | $514,65123 claims |
| NovartisMekinist, Tafinlar | $104 | $343,01522 claims |
| AmgenLumakras | $34 | $298,01114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 379 medical oncology providers in California.
Other medical oncology in Los Angeles
- Stephen LiuLos Angeles$750K
- Jacek PinskiLos Angeles$672K
- Mark AgulnikLos Angeles$303K
- Heinz-Josef LenzLos Angeles$185K
- Syma IqbalLos Angeles$178K
- Anthony El-KhoueiryLos Angeles$156K
- David QuinnLos Angeles$134K
- David TranLos Angeles$128K
- Afsaneh BarziLos Angeles$107K
- Stephen SherwinSan Francisco$6.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.